Arbutus Biopharma Corporation
Arbutus Biopharma Corporation (ABUS) Revenue
Annual & quarterly revenue history · segment & region breakdown
ABUS · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsArbutus Biopharma Corporation trailing twelve-month (TTM) revenue is $0.19B, an increase of 128.21% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | +128.21% |
| 2024-12-31 | $0.01B | -$0.01B | -65.98% |
| 2023-12-31 | $0.02B | -$0.02B | -53.51% |
| 2022-12-31 | $0.04B | +$0.03B | +255.11% |
| 2021-12-31 | $0.01B | +$0.00B | +58.92% |
| 2020-12-31 | $0.01B | +$0.00B | +15.02% |
| 2019-12-31 | $0.01B | +$0.00B | +1.88% |
| 2018-12-31 | $0.01B | -$0.00B | -44.86% |
| 2017-12-31 | $0.01B | +$0.01B | +613.33% |
| 2016-12-31 | $0.00B | -$0.02B | -93.97% |
Compare revenue vs peers
BiotechnologyCompare ABUS revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Arbutus Biopharma Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Arbutus Biopharma Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Arbutus Biopharma Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ABUS revenue · 4 questionsABUS's trailing twelve-month (TTM) revenue is $0.19B. That is an increase of 128.21% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Arbutus Biopharma Corporation SEC filings · GAAP · Arbutus Biopharma Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026